This trial is evaluating whether Laboratory Biomarker Analysis will improve 3 primary outcomes and 3 secondary outcomes in patients with Leukemia. Measurement will happen over the course of 7 days.
This trial requires 2000 total participants across 14 different treatment groups
This trial involves 14 different treatments. Laboratory Biomarker Analysis is the primary treatment being studied. Participants will be divided into 14 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"These signs may include easy bruising or bleeding, swollen lymph nodes, easy fatigue, easy bruising or bleeding, easy bruising or bleeding, and fast heart rate. Symptoms that are not indicative of acute leukemia are more likely signs of cancer. As signs are not a diagnostic criterion they cannot be used to diagnose acute leukemia; they are, however, useful to identify patients at risk of having more serious health problems and to monitor their health for irregularities or problems that warrant urgent medical attention. Patients typically have one or more of these signs. Occasionally, signs of acute leukemia can be present but not reported, such as fever or bone pain (particularly in early disease), and they can occur on top of any other symptoms." - Anonymous Online Contributor
"Leukemia is a cancer of the blood and bone marrow that is diagnosed following the development of bleeding, a fever, or the development of symptoms. This type of cancer is diagnosed in approximately 30% of children and 10% of adults diagnosed with cancer. leukemia.com\n" - Anonymous Online Contributor
"There are multiple causes of leukemia. It can generally be divided into two types of neoplasms, malignant lymphomas and leukemic cell lymphomas. The causes of leukemia are diverse and can be broadly subdivided into: genetic factors; environmental factors; hematologic disease (such as dysplasia, and myelodysplastic syndrome (MDS)), and immunologic disorders. Infection is a cause of leukemia that is also a risk factor for developing other malignancies, especially lymphoma and solid tumor." - Anonymous Online Contributor
"Most of the cancers that are currently treated can be very effectively cured if they are identified and removed before they have spread to other organs and sites. Even for the most common forms of leukemia, cure is achievable. The cure is usually complete, or nearly so, in many forms of leukemia. The cure rate is higher for acute forms of leukemia (80-90%) than for chronic forms (70-80%). In many cases of chronic forms of leukemia, long-term remission (cured disease) is possible, but the disease usually returns if treatment is stopped." - Anonymous Online Contributor
"About 1 out of every 100,000 people suffers a new onset of leukemia annually. Women are affected more often than men. The chance of getting leukemia increases with age at onset. Children who have or acquire ALL are at highest risk for leukemia." - Anonymous Online Contributor
"For all-comers, treatment for [chronic lymphocytic leukemia](https://www.withpower.com/clinical-trials/chronic-lymphocytic-leukemia) involves chemoimmunotherapy-related chemotherapeutic agents. In acute myeloid leukemia, both treatment styles utilize conventional chemotherapy drugs, but most cases also involve targeted therapy agents. Treatment of acute lymphocytic leukemia may also involve non-chemotherapeutic drugs in combination with chemotherapy therapy. All forms of treatment of chronic myeloid leukemia are usually non-curative. All-comers are treated with surgery, and less-aggressive cases (such as early-stage chronic myelogenous leukemia) may also require chemotherapy." - Anonymous Online Contributor
"As most laboratories utilize different assays to measure serum c-Jun N-terminal kinases, we will evaluate the level of serum kinase activity using immunoassay to allow comparison between assays or when they differ." - Anonymous Online Contributor
"What you learn from the scientific research into leukemia in recent years is that there is no such thing as a miracle chemotherapeutic agent. Chemotherapy to treat patients is highly demanding and difficult to achieve. The development of more effective medicines is very rewarding for scientists. The development of targeted therapy, which could be regarded as the “ultimate cancer drug” is just as exciting. This form of chemotherapy, especially target therapy that inhibits or inhibits cancer cell growth, is particularly in need of development. In this review we will show you what scientists believe targeting chemotherapy or targeted therapy can do for human cancer patients. There are a lot of hurdles to overcome in the development of targeted therapy to treat cancer." - Anonymous Online Contributor
"Most patients in this study were elderly and they expressed minimal understanding of trial procedures. Physicians should explain trial procedures and trial potential benefits/harm in an approach that is compatible with patients' ability to understand. Clinicians must also be aware of what potential questions and worries patients have, particularly about the nature of a drug regimen or the length of an intensive therapy regimen." - Anonymous Online Contributor
"The average age a person gets leukemia is about 10.5 years of age. However, not all leukemia may develop until age 10, which would mean that the majority of the people who are diagnosed with leukemia at age 10 are already in remission." - Anonymous Online Contributor
"Significant increases in QoL were evident in survivors of leukemia who completed labbiomarker analysis compared with those who did not. LabBiomarker Analysis is becoming a standard part of diagnostic workup. While the impact on treatment decisions remains unclear, labBiomarkers are bringing important clinical, economic and research benefits for survivors of cancer." - Anonymous Online Contributor
"Recent findings, we identified specific laboratory biomarkers tested for in each case that are useful in selecting the optimal therapy for each patient and can guide treatment recommendations for both newly diagnosed patients and for previously treated patients. It will soon be possible to use similar strategies to identify patient-specific therapeutic biomarkers for use in clinical trials, particularly for clinical trials that include patients with previously treated AML." - Anonymous Online Contributor